Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Front Immunol ; 11: 595342, 2020.
Article in English | MEDLINE | ID: covidwho-1106024

ABSTRACT

The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory pathway (CAP) is a potential therapeutic strategy. However, there is currently no approved drugs targeting the regulatory pathway. It is evident that nicotine, anisodamine and some herb medicine, activate the CAP and exert anti-inflammation action in vitro and in vivo. As the vagus nerve affects both inflammation and specific immune response, we propose that vagus nerve stimulation by invasive or non-invasive devices and acupuncture at ST36, PC6, or GV20, are also feasible approaches to activate the CAP and control COVID-19. It is worth to investigate the efficacy and safety of the strategy in patients with COVID-19.


Subject(s)
COVID-19/therapy , Cytokine Release Syndrome/therapy , Neuroimmunomodulation/immunology , Vagus Nerve Stimulation/methods , Vagus Nerve/immunology , Acupuncture , Anti-Inflammatory Agents/pharmacology , Cytokines/blood , Drugs, Chinese Herbal/pharmacology , Humans , Inflammation/therapy , Nicotine/pharmacology , SARS-CoV-2 , Solanaceous Alkaloids/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL